The ever-increasing armamentarium for the treatment of inflammatory bowel disease (IBD) poses an 'embarrassment of riches', as Dr Charlie Lees (Western General Hospital, United Kingdom) put it. He discussed stratification by disease biology to choose the right drug for the right patient.
It has been neglected for too long that IBD is progressive, according to Dr Lees; the typical pattern being: Patients are diagnosed with active disease, remission is induced but without properly controlling inflammation, the disease will flare and evolve over time. “Once we realise we must not only treat symptoms but also underlying inflammation, we can finally change the natural history of the disease course and offer our patients a much better outlook,” he said. “This means treating early, reducing flare rate, and getting close to a cure for some of our patients. Therefore, early control is everything.” Proof for this concept has emerged from numerous studies of drugs em...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Topical review Next Article
First-ever effective treatment of Charcot-Marie-Tooth disease type 1a »
Table of Contents: ECCO 2019
New Compounds: Study Results
Short-term and Long-term Treatment Results
Complementary and Alternative Medicine
Basic and Preclinical Research
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.